Epigenetic MGMT Test Enters Phase III Brain Cancer Study
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
MDxHealth's epigenetic MGMT test (PredictMDx(TM) for Glioblastoma) will be used to select patients to enroll in a randomized, multicenter phase III clinical study examining the addition of lomustine (also known as CCNU) to the current therapy of temozolomide/radiotherapy in MGMT methylated, newly diagnosed glioblastoma multiforme (GBM) patients, a severe form of brain cancer. The study, called CeTeG, will start recruiting patients this month and will last for approximately 2 years. Financial terms of the deal were not disclosed.
